ストックスクリーナーアプリを入手
0.6838
4.75%
-0.0341
プレマーケット:
.68
-0.0038
-0.56%
前日終値:
$0.7179
開ける：
$0.757
24時間の取引高:
5.53M
Relative Volume:
1.31
時価総額：
$84.47M
収益：
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.4559
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
+7.40%
1か月 パフォーマンス:
-49.72%
6か月 パフォーマンス:
-54.72%
1年 パフォーマンス:
-81.34%
1日の値動き範囲:
$0.6783
$0.8178
1週間の範囲:
$0.5561
$0.8178
52週間の値動き範囲:
$0.4913
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.6838 | 84.47M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | 再開されました | Citigroup | Buy |
| 2024-03-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2024-02-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-29 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-07-27 | ダウングレード | Truist | Buy → Hold |
| 2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 開始されました | Guggenheim | Buy |
| 2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 開始されました | Citigroup | Buy |
| 2022-11-21 | 開始されました | Truist | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-04-29 | 開始されました | BTIG Research | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 開始されました | Robert W. Baird | Outperform |
| 2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation - MSN
Mersana initiated at outperform at William Blair on antibody-drug conjugate potential - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics Inc [MRSN] Shares Rise 18.66 % on Wednesday - Knox Daily
Mersana Therapeutics Updates Investor Presentation Online - TipRanks
Investors in cash trouble should check out Mersana Therapeutics Inc (MRSN) - SETE News
MRSNMersana Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Mersana Therapeutics CEO to Reveal ADC Pipeline Updates at Guggenheim Conference - StockTitan
Apple Swings to Outperformer: Is It a Buy Ahead of Earnings? - The Globe and Mail
MRSN News Today | Why did Mersana Therapeutics stock go down today? - MarketBeat
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $5.57 - MarketBeat
MRSN stock touches 52-week low at $0.56 amid market challenges - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Average Price Target from Analysts - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock touches 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics' SVP sells shares worth $4,912 - MSN
Mersana Therapeutics chief development officer sells shares worth $3,444 - MSN
Mersana Therapeutics CEO sells $2,618 in stock - MSN
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock - MSN
Mersana Therapeutics officer Timothy Lowinger sells $4,667 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock By Investing.com - Investing.com South Africa
Mersana Therapeutics' chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Australia
Mersana Therapeutics CEO sells $2,618 in stock By Investing.com - Investing.com Australia
Mersana Therapeutics' SVP sells shares worth $4,912 By Investing.com - Investing.com South Africa
Mersana Therapeutics SVP sells $2,955 in stock - MSN
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana therapeutics' chief officer sells shares worth $1,130 - MSN
JPMorgan Chase & Co. Grows Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 - MSN
Mersana Therapeutics’ chief accounting officer sells shares worth $2,061 By Investing.com - Investing.com Nigeria
Mersana Therapeutics chief development officer sells shares worth $3,444 By Investing.com - Investing.com South Africa
Mersana therapeutics director Anna Protopapas sells shares worth $5,009 By Investing.com - Investing.com Canada
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):